Johnson & Johnson

2nd Quarter 2022 Results

2nd Quarter 2022 Sales

$24.0B Worldwide Increased ▲ **3.0%**

Excluding acquisitions/ divestitures on an operational basis: Worldwide Increased ▲ **8.1%***

Diluted Earnings Per Share

$1.80 | Decreased ▼ **(23.4)%**

Adjusted Diluted Earnings Per Share*

$2.59 | Increased ▲ **4.4%**





Joaquin Duato
Chief Executive Officer
Johnson & Johnson

"Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company's market leadership in the midst of macroeconomic challenges. I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world."

$3.8 Billion

Worldwide Consumer Health Sales[2]

Consumer Health worldwide reported sales decreased (1.3)%, but increased 2.3% operationally[1]. Primary operational drivers:

Imodium® · Neutrogena® · Stayfree® · Lubriderm® · SUDAFED® · Le Petit Marseillais®

$13.3 Billion

Worldwide Pharmaceutical Sales[2]

Pharmaceutical worldwide reported sales increased 6.7% or 12.3% operationally[1]. Primary operational drivers:

Stelara® (ustekinumab) · DARZALEX® (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL · Tremfya® (guselkumab) · Xarelto® rivaroxaban · Erleada® (apalutamide) 60 mg tablets · Uptravi® selexipag tablets: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg · INVEGA SUSTENNA® paliperidone palmitate

$6.9 Billion

Worldwide MedTech Sales

MedTech worldwide reported sales decreased (1.1)%, but increased 3.4% operationally[1]. Primary operational drivers:

Contact Lens · Electrophysiology · Surgical Vision · Wound Closure · Endocutters · Energy · Trauma · Knees · Hips · Biosurgery

Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on July 19, 2022, available at http://www.investor.jnj.com/sales-earnings.cfm.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[1]Non-GAAP measure; excludes the impact of translational currency.

[2]Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on July 19, 2022, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.